CoChat

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Suppression of TORC1 activity after treatment with RAF or MEK inhibitors predicts drug sensitivity in BRAF -mutant melanoma and can be monitored in patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3005753

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 142

Metadata

Authors
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., Mino-Kenudson, M., Maheswaran, S., Settleman, J., Wargo, J. A., Flaherty, K. T., Haber, D. A., & Engelman, J. A.
Affiliations
  • Harvard University (US)
  • Massachusetts General Hospital (US)
  • Genentech (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
  • Corcoran, Ryan B.
  • Rothenberg, Stephen Michael
  • Haber, Daniel A.
  • Engelman, Jeffrey A.
Venue
Science Translational Medicine
Published
2013-07-31
Volume
5
Issue
196
Pages
196ra98-196ra98
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2161249280
Cited by
140
References
47
Citations by year
2026: 5 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 7 · 2020: 10 · 2019: 8 · 2018: 10 · 2017: 13 · 2016: 9 · 2015: 29 · 2014: 22 · 2013: 5
FWCI
9.71
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (CA-129933, K08CA166510, R01CA129933, R01CA137008)
  • National Institute of Dental and Craniofacial Research (K08DE020139)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
TORC1, BRAF-mutant melanoma, RAF inhibitors, MEK inhibitors, S6 phosphorylation, MAPK signaling, drug resistance, apoptosis, predictive biomarkers, progression-free survival, fine-needle aspiration, targeted therapy response
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Vemurafenib, Animals, Humans, Indoles, Melanoma, Mutation, Phosphorylation, Sulfonamides, Down-Regulation, Apoptosis, Mitogen-Activated Protein Kinase Kinases, Xenograft Model Antitumor Assays, Ribosomal Protein S6, Cell Line, Tumor, Multiprotein Complexes, Protein Kinase Inhibitors, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma. https://app.cochat.ai/papers/10.1126/scitranslmed.3005753
The paper
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., Mino-Kenudson, M., Maheswaran, S., Settleman, J., Wargo, J. A., Flaherty, K. T., Haber, D. A., & Engelman, J. A. (2013). TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3005753

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.